Abstract
In sub-Saharan Africa’s endemic areas for urogenital schistosomiasis, male genital schistosomiasis (MGS) can cause significant morbidity. As part of the Hybridization in UroGenital Schistosomiasis investigation, an MGS sub-study examined a cohort of adult men over a calendar year to better ascertain general infection dynamics and putative zoonotic schistosome transmission. During follow-up, demographic, health and socio-economic data were collected through individual questionnaire interviews. Collected urine and semen were analysed using urine filtration, urine and semen microscopy and molecular DNA analyses of semen. Ten participants with reported MGS-associated symptoms had Schistosoma eggs in their urine and semen at 6-month follow-up, with seven at 12 months. Ten out of 11 participants with Schistosoma haematobium eggs on semen microscopy at baseline had persistent infection at 6-month follow-up, together with 6 new participants, giving an MGS prevalence of 84·2% (n = 19). Two also had Schistosoma mattheei eggs co-infection. Four of the 13 participants at 12-month follow-up had S. haematobium eggs in their semen which were persistent at all the time points. Using semen PCR, 14 participants (73·7%) had Schistosoma infection at 6 months, with only 2 participants being infected for first time. Upon DNA analysis, three participants also had hybrid co-infection at this time point. At 12 months, only 6 participants had Schistosoma infection with no hybrids detected. In summary, like S. haematobium and despite praziquantel treatment, both zoonotic and hybrid schistosomes can continue to cause MGS, which pose a further tangible challenge in future management and control measures.
Keywords: hybrid, Lake Malawi, MGS, praziquantel, Schistosoma haematobium, Schistosoma mattheei, semen, Shire river
Introduction
The WHO published a road map for control and elimination of neglected tropical diseases (NTDs) 2021–2030 of which one of their public health targets is specific for schistosomiasis (WHO, 2022). Despite being targeted for elimination as a public health problem, schistosomiasis is one of the NTDs that continue to affect millions of people, particularly in resource-limited regions of the world (McManus et al. 2018; Buonfrate et al. 2025). Despite being a major public health issue in many tropical and subtropical countries, schistosomiasis has often been overlooked in global health discussions and funding priorities. In sub-Saharan Africa (SSA), male genital schistosomiasis (MGS), a gender-specific manifestation of urogenital schistosomiasis in men, has a long history of being an under-recognized and under-reported largely due to limited awareness and access to diagnostic tools, particularly resource poor rural areas where urogenital schistosomiasis is endemic (Bustinduy et al. 2022). This is in contrast with female genital schistosomiasis (FGS) which has been widely studied, diagnostic, management and control strategies developed and advocated (WHO, 2015).
The condition, MGS, was first described in 1911 (Madden, 1911), though it likely existed much earlier in SSA and the Middle East regions, where Schistosoma haematobium was prevalent (Kayuni et al. 2019a). Men infected after exposure to schistosome cercariae-infested water bodies were observed to have genital lesions, including fibrosis in scrotum, prostate and seminal vesicles, testicular atrophy, and even infertility due to inflammatory response to tissue eggs deposition (Costain et al. 2018).
In recent years, it has been demonstrated that S. haematobium has an innate capacity to form viable hybrids with other schistosome species, particularly with Schistosoma mattheei, a common species of animal schistosome found in livestock (Stothard et al. 2020, 2024). Hybridization is a well-established evolutionary mechanism that contributes to genetic diversity, allowing species to adapt more quickly to environmental changes (Mawa et al. 2021). In light of the future challenge to interrupt schistosome transmission, there is growing interest in hybrid schistosomes, and their environmental dynamics, resulting from crossbreeding between zoonotic and human Schistosoma species. Furthermore, such introgressed or hybrid variants can potentially complicate the clinical picture of urogenital schistosomiasis and how the parasite is evolving and adapting to different hosts (Rey et al. 2021; Kayuni et al. 2024b).
Certainly, zoonotic schistosomes have contributed significantly to the overall burden of schistosomiasis in humans, with some causing fibrosis and calcification in prostate, seminal vesicles and testes (Buonfrate et al. 2025; Léger et al. 2020). Advancements in molecular biology significantly improved modern diagnostic tools for schistosomiasis, including MGS where detection of Schistosoma eggs, DNA and antigens can be made directly from semen, prostate biopsies, and other tissue samples, offering more precise and reliable diagnosis (Cunningham et al. 2024, Rinaldi et al. 2015).
Following a baseline MGS survey within the longitudinal study entitled Hybridization of UroGenital Schistosomiasis (HUGS) in Mangochi and Nsanje districts, Southern Malawi (Kayuni et al. 2024a), a clinical 12-month follow-up was conducted on participating men to describe progression of schistosome infections either from human, zoonotic and hybrid worms undertaken between June 2023 and July 2024.
Materials and methods
Study sites
This MGS longitudinal study was conducted in the two sentinel communities at Samama and at Mthawira in Mangochi and Nsanje Districts, respectively (Figure 1). Here, hybrid infections have previously been identified in school children in these communities, with a tenth of infected children shedding atypical eggs in urine, alongside ectopic egg patent S. mansoni and zoonotic eggs, at the baseline of the HUGS study in 2022.
Figure 1.
Map showing two study communities around Samama School in Mangochi District and Mthawira School in Nsanje District of Southern Malawi where participates came from.
Study population
The study population comprised of all males aged between 18 and 45 years old who had active egg-patent schistosomiasis at baseline in 2022 in the two study sites of Samama and Mthawira areas. These were recruited as at baseline of the MGS study in June and July 2023 and underwent a 6- and 12-month follow-up. Written informed consent was sought after adequate awareness before enrolment into the study. All participants were provided a directly observed treatment with praziquantel standard dose, 40 mg/kg body weight, at the end of each study visit.
Data collection
Demographic data were gathered through individual questionnaire interviews to collect details on participants’ health, socio-economic status, water contact habits, livestock availability and symptoms associated with MGS (Kayuni et al. 2024a).
Urine and semen microscopy
A 120 mL clear container was used to collect a urine sample during the study visit, which was then filtered and examined microscopically to detect Schistosoma eggs in 10 mL of the well-mixed sample (Cheesbrough, 2005). Additionally, each sample underwent reagent dipstick testing and point-of-care circulating cathodic antigen (POC-CCA) analysis for detection of intestinal schistosomiasis. Participants were then requested to provide a semen sample, which was collected in a clear plastic bag for direct field microscopy (Kayuni et al. 2019b). The samples were subsequently centrifuged, and the sediments were re-examined microscopically. These sediments were preserved in 1 mL of 70% ethanol to prepare for shipment to Liverpool School of Tropical Medicine (LSTM) in the United Kingdom.
Molecular analyses
As previously described (Cunningham et al. 2024; Kayuni et al. 2024a), molecular analysis of the semen sediments included High-Resolution Melt (HRM) and TaqMan® real-time PCR for Schistosoma spp. DNA markers for viral infection with HPV were also screened for using the QIAscreen HPV PCR Test kit (Qiagen, Manchester, UK), capable of screening for two high-risk genotypes, 16 and 18 alongside the others. Also, seminal sediments were analysed for other STIs such as Chlamydia trachomatis, Trichomonas vaginalis, Herpes simplex virus (HSV) 1, HSV 2, Candida spp., Ureaplasma spp., M. hominis, S. agalactiae using the EasyScreen™ STI Kit (SydPath, Sydney, Australia).
Data analyses
The results of the diagnostic tests were analysed using non-parametric tests due to the small sample size and non-normal distribution. These were tabulated and presented accordingly.
Ethical considerations
Ethical approval for the study was granted by the College of Medicine Research Ethics Committee (COMREC), Kamuzu University of Health Sciences (KUHeS), Malawi, (Approval number: P.08/21/3381) and the LSTM Research Ethics Committee (LSTM REC) in the United Kingdom (registration number: 22-028). Informed consent to participate in the study was obtained from all of the participants. Privacy and confidentiality were maintained throughout the study. All participants including those who had Schistosoma eggs in urine and/or semen were provided a directly observed treatment with praziquantel standard dose, 40 mg/kg body weight, at each time point. Appropriate referral for treatment and management was provided to participants who had other infections.
Results
Of the 22 male participants recruited into the MGS sub-study at baseline in June 2023, 19 (7 in Nsanje, 12 in Mangochi) and 14 (3 in Nsanje, 11 in Mangochi) participants were available for follow-up at 6- and 12-month time points, respectively (Table 1).
Table 1.
Demographical information and laboratory findings of the participants at all the time points
ID |
Age (years) |
Urine filtration egg count |
Semen microscopy |
Observations on semen microscopy |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline |
6 months |
12 months |
Baseline |
6 months |
12 months |
Baseline |
6 months |
12 months |
|||||
S. h. |
S. matt. |
S. h. |
S. matt. |
S. h. |
S. matt. |
||||||||
eggs |
eggs |
eggs |
eggs |
eggs |
eggs |
||||||||
A |
19 |
1−9 |
0 |
0 |
8 |
1 |
9 |
0 |
2 (cal) |
0 |
Normal |
Normal |
Normal |
B |
18 |
50+ |
0 |
0 |
25 |
0 |
5 |
0 |
0 |
0 |
Normal |
Normal |
Normal |
C |
18 |
10−49 |
1−9 |
0 |
6 |
0 |
8 |
0 |
0 |
0 |
Haemospermia (blood in semen), loose consistency, azoospermia |
Loose consistency, azoospermia |
Loose consistency, azoospermia |
D |
18 |
0 |
0 |
0 |
15 |
0 |
10 |
0 |
1 (cal) |
0 |
Colour change, loose consistency, azoospermia |
Normal |
Normal |
E |
21 |
0 |
1−9 |
0 |
2 |
0 |
3 |
0 |
0 |
0 |
Normal |
Few live spermatozoa |
Some fragmented spermatozoa |
F |
28 |
0 |
0 |
0 |
0 |
0 |
6 |
0 |
0 |
0 |
Normal |
Normal |
Normal |
G |
27 |
1−9 |
0 |
0 |
1 |
0 |
8 |
2 |
2 |
1 |
Normal |
Dead spermatozoa |
Dead spermatozoa |
H |
19 |
0 |
N/A |
N/A |
5 |
0 |
N/A |
N/A |
N/A |
N/A |
Normal |
N/A |
N/A |
I |
30 |
1−9 |
10−49 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Normal |
Normal |
Normal |
J |
22 |
10−49 |
0 |
50+ |
9 |
0 |
7 |
0 |
N/A |
N/A |
Normal |
Normal |
Normal |
K |
18 |
0 |
N/A |
N/A |
0 |
0 |
N/A |
N/A |
N/A |
N/A |
Normal |
N/A |
N/A |
L |
21 |
0 |
1−9 |
1−9 |
0 |
0 |
4 |
0 |
0 |
0 |
Normal |
Dead spermatozoa |
1/3 dead spermatozoa |
M |
18 |
10−49 |
50+ |
10−49 |
100 |
0 |
8 |
1 |
4 |
0 |
Haemospermia, loose consistency, dead spermatozoa |
Azoospermia |
Loose consistency, azoospermia |
N |
32 |
1−9 |
50+ |
N/A |
0 |
0 |
7 |
0 |
N/A |
N/A |
Normal |
Normal |
N/A |
O |
32 |
0 |
N/A |
N/A |
0 |
0 |
N/A |
N/A |
N/A |
N/A |
Normal |
Normal |
Normal |
P |
39 |
0 |
0 |
1−9 |
0 |
0 |
10 |
0 |
0 |
0 |
Normal |
Normal |
Normal |
Q |
30 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Normal |
Normal |
Azoospermia |
R |
26 |
0 |
10−49 |
N/A |
0 |
0 |
7 |
0 |
N/A |
N/A |
Normal |
Normal |
N/A |
S |
19 |
0 |
0 |
0 |
1 |
0 |
3 |
0 |
0 |
0 |
Normal |
Cloudy, loose consistency |
Cloudy, loose consistency, azoospermia |
T |
22 |
0 |
10−49 |
N/A |
0 |
0 |
0 |
0 |
N/A |
N/A |
Normal |
Normal |
N/A |
U |
22 |
1−9 |
1−9 |
N/A |
500 |
0 |
10 |
0 |
N/A |
N/A |
Normal |
Normal |
N/A |
V |
25 |
1−9 |
0 |
N/A |
0 |
0 |
8 |
0 |
N/A |
N/A |
Normal |
Normal |
N/A |
Note: S. h. = Schistosoma haematobium, S. matt. = Schistosoma mattheei, N/A = not available.
Three participants (J, L and O) reported symptoms associated with MGS at baseline, namely blood in semen (haemospermia), sores and pain in the genitalia, pain during coitus and ejaculation (Table 2). Only one participant (J) with symptoms had Schistosoma eggs in their urine and semen. At 6-month follow-up, 10 participants reported MGS symptoms while 7 participants reported the symptoms at 12-month follow-up time point.
Table 2.
Symptoms of MGS experienced by the participants at all the time points
Symptoms |
A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
K |
L |
M |
N |
O |
P |
Q |
R |
S |
T |
U |
V |
N in cohort |
||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Time point 1 – June 2023 |
Urinary |
Fever |
1 |
1 |
1 |
0 |
0 |
0 |
1 |
0 |
1 |
1 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
9 |
Headache |
1 |
1 |
1 |
0 |
0 |
0 |
1 |
0 |
1 |
1 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
9 |
||
Fatigue |
1 |
1 |
1 |
0 |
0 |
0 |
1 |
0 |
1 |
1 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
8 |
||
Abdominal pain |
1 |
1 |
1 |
0 |
0 |
0 |
1 |
0 |
1 |
1 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
5 |
||
Dysuria |
1 |
1 |
1 |
0 |
0 |
0 |
1 |
0 |
1 |
1 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
7 |
||
Polyuria |
1 |
1 |
1 |
0 |
0 |
0 |
1 |
0 |
1 |
1 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
10 |
||
Discoloured Urine |
1 |
1 |
1 |
0 |
0 |
0 |
1 |
0 |
1 |
1 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
8 |
||
Haematuria |
1 |
1 |
1 |
0 |
0 |
0 |
1 |
0 |
1 |
1 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
6 |
||
Blood in stool |
1 |
1 |
1 |
0 |
0 |
0 |
1 |
0 |
1 |
1 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
||
Genital |
Haemospermia |
1 |
1 |
1 |
1 |
1 |
0 |
1 |
1 |
0 |
1 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
0 |
1 |
|
Dyspareunia |
1 |
1 |
1 |
1 |
1 |
0 |
1 |
1 |
0 |
1 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
0 |
2 |
||
Dysorgasmia |
1 |
1 |
1 |
1 |
1 |
0 |
1 |
1 |
0 |
1 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
0 |
2 |
||
Genital pain |
1 |
1 |
1 |
1 |
1 |
0 |
1 |
1 |
0 |
1 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
0 |
2 |
||
Genital sores |
1 |
1 |
1 |
1 |
1 |
0 |
1 |
1 |
0 |
1 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
1 |
0 |
3 |
||
N sx experienced |
0 |
3 |
0 |
0 |
6 |
4 |
1 |
0 |
1 |
13 |
0 |
6 |
6 |
2 |
11 |
2 |
3 |
7 |
1 |
4 |
1 |
3 |
|||
Time point 2 – January 2024 |
Urinary |
Fever |
0 |
0 |
1 |
0 |
1 |
0 |
0 |
N/A |
1 |
0 |
N/A |
1 |
1 |
1 |
N/A |
0 |
0 |
1 |
0 |
0 |
1 |
0 |
12 |
Headache |
0 |
0 |
1 |
0 |
1 |
0 |
0 |
N/A |
1 |
0 |
N/A |
1 |
1 |
1 |
N/A |
0 |
0 |
1 |
0 |
0 |
1 |
0 |
17 |
||
Fatigue |
0 |
0 |
1 |
0 |
1 |
0 |
0 |
N/A |
1 |
0 |
N/A |
1 |
1 |
1 |
N/A |
0 |
0 |
1 |
0 |
0 |
1 |
0 |
11 |
||
Abdominal pain |
0 |
0 |
1 |
0 |
1 |
0 |
0 |
N/A |
1 |
0 |
N/A |
1 |
1 |
1 |
N/A |
0 |
0 |
1 |
0 |
0 |
1 |
0 |
16 |
||
Dysuria |
0 |
0 |
1 |
0 |
1 |
0 |
0 |
N/A |
1 |
0 |
N/A |
1 |
1 |
1 |
N/A |
0 |
0 |
1 |
0 |
0 |
1 |
0 |
12 |
||
Polyuria |
0 |
0 |
1 |
0 |
1 |
0 |
0 |
N/A |
1 |
0 |
N/A |
1 |
1 |
1 |
N/A |
0 |
0 |
1 |
0 |
0 |
1 |
0 |
13 |
||
Discoloured Urine |
0 |
0 |
1 |
0 |
1 |
0 |
0 |
N/A |
1 |
0 |
N/A |
1 |
1 |
1 |
N/A |
0 |
0 |
1 |
0 |
0 |
1 |
0 |
15 |
||
Haematuria |
0 |
0 |
1 |
0 |
1 |
0 |
0 |
N/A |
1 |
0 |
N/A |
1 |
1 |
1 |
N/A |
0 |
0 |
1 |
0 |
0 |
1 |
0 |
11 |
||
Blood in stool |
0 |
0 |
1 |
0 |
1 |
0 |
0 |
N/A |
1 |
0 |
N/A |
1 |
1 |
1 |
N/A |
0 |
0 |
1 |
0 |
0 |
1 |
0 |
5 |
||
Genital |
Haemospermia |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
N/A |
0 |
1 |
N/A |
1 |
1 |
1 |
N/A |
1 |
0 |
1 |
1 |
0 |
1 |
1 |
3 |
|
Dyspareunia |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
N/A |
0 |
1 |
N/A |
1 |
1 |
1 |
N/A |
1 |
0 |
1 |
1 |
0 |
1 |
1 |
3 |
||
Dysorgasmia |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
N/A |
0 |
1 |
N/A |
1 |
1 |
1 |
N/A |
1 |
0 |
1 |
1 |
0 |
1 |
1 |
5 |
||
Genital pain |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
N/A |
0 |
1 |
N/A |
1 |
1 |
1 |
N/A |
1 |
0 |
1 |
1 |
0 |
1 |
1 |
7 |
||
Genital sores |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
N/A |
0 |
1 |
N/A |
1 |
1 |
1 |
N/A |
1 |
0 |
1 |
1 |
0 |
1 |
1 |
3 |
||
N sx experienced |
4 |
12 |
7 |
0 |
4 |
8 |
8 |
0 |
3 |
7 |
0 |
11 |
10 |
5 |
0 |
5 |
10 |
12 |
6 |
5 |
3 |
8 |
|||
Time point 3 – June 2024 |
Urinary |
Fever |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
0 |
1 |
N/A |
1 |
1 |
N/A |
N/A |
1 |
0 |
N/A |
0 |
N/A |
N/A |
N/A |
9 |
Headache |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
0 |
1 |
N/A |
1 |
1 |
N/A |
N/A |
1 |
0 |
N/A |
0 |
N/A |
N/A |
N/A |
12 |
||
Fatigue |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
0 |
1 |
N/A |
1 |
1 |
N/A |
N/A |
1 |
0 |
N/A |
0 |
N/A |
N/A |
N/A |
6 |
||
Abdominal pain |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
0 |
1 |
N/A |
1 |
1 |
N/A |
N/A |
1 |
0 |
N/A |
0 |
N/A |
N/A |
N/A |
8 |
||
Dysuria |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
0 |
1 |
N/A |
1 |
1 |
N/A |
N/A |
1 |
0 |
N/A |
0 |
N/A |
N/A |
N/A |
7 |
||
Polyuria |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
0 |
1 |
N/A |
1 |
1 |
N/A |
N/A |
1 |
0 |
N/A |
0 |
N/A |
N/A |
N/A |
8 |
||
Discoloured Urine |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
0 |
1 |
N/A |
1 |
1 |
N/A |
N/A |
1 |
0 |
N/A |
0 |
N/A |
N/A |
N/A |
8 |
||
Haematuria |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
0 |
1 |
N/A |
1 |
1 |
N/A |
N/A |
1 |
0 |
N/A |
0 |
N/A |
N/A |
N/A |
7 |
||
Blood in stool |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
0 |
1 |
N/A |
1 |
1 |
N/A |
N/A |
1 |
0 |
N/A |
0 |
N/A |
N/A |
N/A |
5 |
||
Genital |
Haemospermia |
1 |
0 |
0 |
1 |
0 |
0 |
1 |
N/A |
0 |
N/A |
N/A |
0 |
1 |
N/A |
N/A |
0 |
0 |
N/A |
0 |
N/A |
N/A |
N/A |
2 |
|
Dyspareunia |
1 |
0 |
0 |
1 |
0 |
0 |
1 |
N/A |
0 |
N/A |
N/A |
0 |
1 |
N/A |
N/A |
0 |
0 |
N/A |
0 |
N/A |
N/A |
N/A |
3 |
||
Dysorgasmia |
1 |
0 |
0 |
1 |
0 |
0 |
1 |
N/A |
0 |
N/A |
N/A |
0 |
1 |
N/A |
N/A |
0 |
0 |
N/A |
0 |
N/A |
N/A |
N/A |
4 |
||
Genital pain |
1 |
0 |
0 |
1 |
0 |
0 |
1 |
N/A |
0 |
N/A |
N/A |
0 |
1 |
N/A |
N/A |
0 |
0 |
N/A |
0 |
N/A |
N/A |
N/A |
6 |
||
Genital sores |
1 |
0 |
0 |
1 |
0 |
0 |
1 |
N/A |
0 |
N/A |
N/A |
0 |
1 |
N/A |
N/A |
0 |
0 |
N/A |
0 |
N/A |
N/A |
N/A |
4 |
||
N sx experienced |
0 |
8 |
8 |
4 |
14 |
11 |
8 |
0 |
14 |
8 |
0 |
1 |
3 |
0 |
0 |
7 |
0 |
0 |
3 |
0 |
0 |
0 |
|||
Note: Within the table: red colour = symptom experienced, 1 = Schistosoma eggs in urine or semen, 0 = no Schistosoma eggs in urine or semen, N/A = urine or semen sample not available for analysis.
Five of the 10 participants who had Schistosoma eggs in their urine at baseline, remained egg-patent at 6-month follow-up, with 4 participants (E, L, R and T) who were urinary egg-patent for the first time, giving a prevalence of 47·4% (n = 19). At 12-month follow-up, 7 out of the 10 participants with Schistosoma eggs in their urine at baseline were present and participant J was urinary egg-patent at baseline and this time point while participant M was infected at all 3 time points. In total, 4 (J, L, M and P) had eggs in their urine (28·6%, n = 14) at this time point (Figure 2).
Figure 2.
Map showing findings of semen microscopy of the study participants alongside those of urine filtration in the 2 communities around Samama school in Mangochi district and Mthawira school in Nsanje district of Southern Malawi where participants came from.
On semen microscopy, 10 out of 11 participants with S. haematobium eggs at baseline had persistent infection at 6-month follow-up, together with 6 participants who had eggs in their semen for the first time, showing a higher infection rate of 84·2% (n = 19). Two participants, G and M, also had S. mattheei eggs in semen.
Of the 13 participants who were available at 12-month follow-up, only 4 (A, D, G and M) had S. haematobium eggs in their semen which were persistent at all the time points, with 1 (participant G) having persistent S. mattheei eggs from 6-month follow-up, depicting a dual human and zoonotic infection at both time points. Two participants (A and D) had calcified S. haematobium eggs at this time point.
Only 1 of the 3 participants, D, who had changes in his semen observed at baseline, had normal features at subsequent follow-up time points. However, 4 additional participants (E, G, L and S) who also had Schistosoma eggs in their semen were observed to have abnormal changes ranging from loose semen consistency, few live or dead spermatozoa to azoospermia at 6- and 12-month time points.
Using real time PCR at 6-month follow-up, 14 of the 19 participants (73·7%) were positive for Schistosoma infection, with only 2 participants (E and R) who were infected for first time at this time point (Table 3 and Supplementary Table 1). Three participants had a possible hybrid infection at this time point. On 12-month follow-up, only 6 out of 13 participants had positive Schistosoma infection with no possible hybrid infection. All in all, only 6 of all recruited participants (B, C, F, L, P and S) had no positive Schistosoma infection on PCR at the end of the study.
Table 3.
Results of molecular analysis on Schistosoma infection using real-time PCR of the participants’ semen
Participant ID |
Age (years) |
Baseline |
6 months |
12 months |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gen |
Mito |
HRM Tm1 |
HRM Tm2 |
Gen |
Mito |
HRM Tm1 |
HRM Tm2 |
Gen |
Mito |
HRM Tm1 |
HRM Tm2 |
||
A |
19 |
Sh |
Smat |
Smat |
0·0 |
Sh |
0·0 |
Smat |
0·0 |
Sh |
Smat |
Smat |
0·0 |
B |
18 |
Sh |
Sm |
Sm |
0·0 |
Shyp |
Shyp |
Shyp |
Shyp |
0·0 |
0·0 |
0·0 |
0·0 |
C |
18 |
Sh |
Smat |
Smat |
0·0 |
Sh |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
D |
18 |
Sh |
0·0 |
0·0 |
0·0 |
Sh |
Sc |
Sc |
0·0 |
Sh |
0·0 |
0·0 |
0·0 |
E |
21 |
0·0 |
0·0 |
0·0 |
0·0 |
Sh |
Smat |
Smat |
0·0 |
Sh |
0·0 |
0·0 |
0·0 |
F |
28 |
Shyp |
0·0 |
Shyp |
Sm |
Sh |
Smat |
Smat |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
G |
27 |
Sh |
Smat |
Smat |
0·0 |
Sh |
Smat |
Smat |
0·0 |
Sh |
Smat |
Smat |
0·0 |
H |
19 |
Sh |
0·0 |
0·0 |
0·0 |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
I |
30 |
Sh |
0·0 |
0·0 |
0·0 |
Sh |
0·0 |
0·0 |
0·0 |
Sh |
0·0 |
0·0 |
0·0 |
J |
22 |
Sh |
0·0 |
0·0 |
0·0 |
Sh |
Sc |
Sc |
0·0 |
N/A |
N/A |
N/A |
N/A |
K |
18 |
0·0 |
0·0 |
0·0 |
0·0 |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
L |
21 |
Sh |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
M |
18 |
Sh |
0·0 |
0·0 |
0·0 |
Shyp |
Shyp |
Shyp |
0·0 |
Sh |
0·0 |
0·0 |
0·0 |
N |
32 |
Sh |
Sm |
Sm |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
N/A |
N/A |
N/A |
N/A |
O |
32 |
0·0 |
0·0 |
0·0 |
0·0 |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
P |
39 |
Sh |
0·0 |
0·0 |
0·0 |
Sh |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
Q |
30 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
R |
26 |
0·0 |
0·0 |
0·0 |
0·0 |
Shyp |
Shyp |
Shyp |
0·0 |
N/A |
N/A |
N/A |
N/A |
S |
19 |
Sh |
0·0 |
0·0 |
0·0 |
Sh |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
T |
22 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
N/A |
N/A |
N/A |
N/A |
U |
22 |
Sh |
0·0 |
0·0 |
0·0 |
Sh |
Sc |
Sc |
0·0 |
N/A |
N/A |
N/A |
N/A |
V |
25 |
0·0 |
Smat |
Smat |
0·0 |
0·0 |
0·0 |
0·0 |
0·0 |
N/A |
N/A |
N/A |
N/A |
Note: Gen = generic, Mito = mitochondrial, HRM = high-resolution melt, Tm = melting temperature, N/A = not available; Sh = Schistosoma haematobium, Sm = Schistosoma mansoni, Smat = Schistosoma mattheei, Sc = Schistosoma curassoni, Shyp = Schistosoma hybrid, 0·0 = no Schistosoma detected; colours: dark blue = Schistosoma haematobium; plum = Schistosoma mansoni; dark green = Schistosoma mattheei; orange = Schistosoma curassoni; red = Schistosoma hybrid.
Of those participants who had Schistosoma eggs in semen during the study, 4 had none in urine (D, F, G and S). Furthermore, participants Q and T had no eggs in urine nor semen, also with negative PCR.
All the 12 (54·5%) participants who had detectable HPV serotypes 16 and 18 in semen, associated with penile and cervical carcinoma at baseline, had no HPV detected during follow-up at both time points (Table 4 and Supplementary Table 2). On STIs, particularly T. vaginalis, only one participant was positive at 6-month follow-up and none at 12-month follow-up, showing a downward trend of both infections.
Table 4.
Results of the real time PCR for Human Papilloma Virus (HPV) serotypes and STIs – Trichomonas vaginalis in comparison with and Schistosoma species
Participant ID |
Age (years) |
Baseline |
6 months |
12 months |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gen |
HRM Tm1 |
HRM Tm2 |
HPV type |
STI Tv |
Gen |
HRM Tm1 |
HRM Tm2 |
HPV type |
STI Tv |
Gen |
HRM Tm1 |
HRM Tm2 |
HPV type |
STI Tv |
||
A |
19 |
Sh |
Smat |
Smat |
16 |
0·0 |
Sh |
Smat |
0·0 |
– |
0·0 |
Sh |
Smat |
Smat |
– |
0·0 |
B |
18 |
Sh |
Sm |
Sm |
Other |
0·0 |
Shyp |
Shyp |
Shyp |
– |
0·0 |
0·0 |
0·0 |
0·0 |
– |
0·0 |
C |
18 |
Sh |
Smat |
Smat |
Other |
0·0 |
Sh |
0·0 |
0·0 |
– |
0·0 |
0·0 |
0·0 |
0·0 |
– |
0·0 |
D |
18 |
Sh |
0·0 |
0·0 |
18 |
0·0 |
Sh |
Sc |
0·0 |
– |
0·0 |
Sh |
0·0 |
0·0 |
– |
0·0 |
E |
21 |
0·0 |
0·0 |
0·0 |
Other |
0·0 |
Sh |
Smat |
0·0 |
– |
0·0 |
Sh |
0·0 |
0·0 |
– |
0·0 |
F |
28 |
Shyp |
Shyp |
Sm |
16 |
0·0 |
Sh |
Smat |
0·0 |
– |
0·0 |
0·0 |
0·0 |
0·0 |
– |
0·0 |
G |
27 |
Sh |
Smat |
0·0 |
18 |
0·0 |
Sh |
Smat |
0·0 |
– |
0·0 |
Sh |
Smat |
Smat |
– |
0·0 |
H |
19 |
Sh |
0·0 |
0·0 |
Other |
0·0 |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
I |
30 |
Sh |
0·0 |
0·0 |
16 |
Tv |
Sh |
0·0 |
0·0 |
– |
0·0 |
Sh |
0·0 |
0·0 |
– |
0·0 |
J |
22 |
Sh |
0·0 |
0·0 |
– |
0·0 |
Sh |
Sc |
0·0 |
– |
0·0 |
N/A |
N/A |
N/A |
N/A |
N/A |
K |
18 |
0·0 |
0·0 |
0·0 |
– |
Tv |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
L |
21 |
Sh |
0·0 |
0·0 |
Other |
Tv |
0·0 |
0·0 |
0·0 |
– |
0·0 |
0·0 |
0·0 |
0·0 |
– |
0·0 |
M |
18 |
Sh |
0·0 |
0·0 |
– |
Tv |
Shyp |
Shyp |
0·0 |
– |
0·0 |
Sh |
0·0 |
0·0 |
– |
0·0 |
N |
32 |
Sh |
Sm |
0·0 |
16 |
Tv |
0·0 |
0·0 |
0·0 |
– |
0·0 |
N/A |
N/A |
N/A |
N/A |
N/A |
O |
32 |
0·0 |
0·0 |
0·0 |
– |
0·0 |
N/A |
N/A |
N/A |
– |
0·0 |
N/A |
N/A |
N/A |
N/A |
N/A |
P |
39 |
Sh |
0·0 |
0·0 |
Other |
Tv |
Sh |
0·0 |
0·0 |
– |
0·0 |
0·0 |
0·0 |
0·0 |
– |
0·0 |
Q |
30 |
0·0 |
0·0 |
0·0 |
– |
0·0 |
0·0 |
0·0 |
0·0 |
– |
0·0 |
0·0 |
0·0 |
0·0 |
– |
0·0 |
R |
26 |
0·0 |
0·0 |
0·0 |
– |
0·0 |
Shyp |
Shyp |
0·0 |
– |
Tv |
N/A |
N/A |
N/A |
N/A |
N/A |
S |
19 |
Sh |
0·0 |
0·0 |
– |
0·0 |
Sh |
0·0 |
0·0 |
– |
0·0 |
0·0 |
0·0 |
0·0 |
– |
0·0 |
T |
22 |
0·0 |
0·0 |
0·0 |
– |
0·0 |
0·0 |
0·0 |
0·0 |
– |
0·0 |
N/A |
N/A |
N/A |
N/A |
N/A |
U |
22 |
Sh |
0·0 |
0·0 |
– |
0·0 |
Sh |
Sc |
0·0 |
– |
0·0 |
N/A |
N/A |
N/A |
N/A |
N/A |
V |
25 |
0·0 |
Smat |
0·0 |
– |
0·0 |
0·0 |
0·0 |
0·0 |
– |
0·0 |
N/A |
N/A |
N/A |
N/A |
N/A |
Note: Gen = generic, HRM = high-resolution melt, Tm = melting temperature, Tv = T. vaginalis; N/A = not available, Sh = Schistosoma haematobium, Sm = Schistosoma mansoni, Smat = Schistosoma mattheei, Sc = Schistosoma curassoni, Shyp = Schistosoma hybrid, 0·0 = no Schistosoma detected; colours: dark blue = Schistosoma haematobium; plum = Schistosoma mansoni; dark green = Schistosoma mattheei; orange = Schistosoma curassoni; red = Schistosoma hybrid; yellow = HPV serotypes 16 or 18 or others; purple = T. vaginalis.
Discussion
As described previously, here in these 2 southern communities of Malawi, MGS remains a seldomly recognised, undiagnosed condition in endemic areas, where it is as commonly prevalent as urogenital schistosomiasis, and with coinfection signatures with S. mattheei (Kayuni et al. 2024a). This study is a 12-month follow-up to our initial study comprising a cohort of 22 men where Schistosoma eggs was detected in semen of 11 men (50·0%) with 16 men (72·7%) positive on real-time PCR for Schistosoma infection, conducted at 2 time points of 6 months each. It was noted that despite taking a directly observed standard dose of praziquantel treatment, 40 mg/kg body weight, some participants had persistent or possible re-infections.
An important observation is that four participants had Schistosoma eggs only in semen during the study, which is consistent with similar studies, showing that the individuals can have MGS due to worms inhabiting the blood vessels around the genital organs, rather than contamination of the urethra from urinary schistosomiasis (Kayuni et al. 2019a, 2021; Bustinduy et al. 2022). Hence, the critical importance of analysing semen samples as a way of diagnosing MGS.
Previous reports on MGS associated with non-human schistosomes have been inadequate and mostly case reports of people visiting to endemic areas, despite studies done in Malawi and Madagascar describing significant burden of MGS (Leutscher et al. 2000; Kayuni et al. 2021, 2023a). Furthermore, the extent of the morbidity resulting from these zoonotic and hybrid MGS infections remains poorly understood although these schistosomes in SSA are increasingly becoming recognized as an emerging public health problem (Webster et al. 2019; Stothard et al. 2020) and future challenge in gaining adequate environmental transmission control (Stothard et al. 2024).
The proximity of most study participants to domesticated livestock such as goats, sheep and cattle in the study area which have shown to harbour both human and zoonotic mixed infections (Juhász et al. 2024a, 2024b) could have significantly contributed to the level of MGS. Certainly, some participants were observed to have hybrid infections during the follow-up using our novel two-tube real-time PCR (Cunningham et al. 2024), which brings about the need for advanced molecular diagnostics to improve detection of such diseases. Furthermore, one health initiatives can aid in addressing the emerging zoonotic and hybrid infections which is being worsened with adverse climate change, thereby affecting efforts in the control and elimination of schistosomiasis as public health problem in endemic areas (Mbabazi et al. 2011; Shukla et al. 2023).
Although some participants had changes in their semen, namely haemospermia, changes in semen colour and consistency and azoospermia which have also been reported in other studies, only one had resolved these abnormalities during follow-up. This highlights the need for earlier treatment with praziquantel to experience its beneficial effects, apart from other interventions to prevent such infections as well as improving diagnostic services, healthcare professional awareness and capacity in disease management (Mbabazi et al. 2011; Shukla et al. 2023).
Certainly, most health facilities in the endemic areas use the syndromic approach in the STI management (WHO 2005, 2021). These genital symptoms utilized are similar to those attributed to MGS, also observed in our study, which can result in under-diagnosis and inappropriate management. Also, MGS has been observed to play a role in the progression of other infections such as human immunodeficiency virus (HIV) among other factors, as previously observed in increasing seminal viral load of dually infected men (Midzi et al. 2017; Kayuni et al. 2023b). Therefore, there is need for more advocacy for appropriate diagnostic and management resources together with awareness and capacity building among community people and healthcare providers in schistosomiasis-endemic areas.
As earlier alluded to, the study was limited in the low number of study participants owing to the sensitivity of the condition which calls for larger stratified studies in other endemic areas to provide a representative picture of the MGS outcome.
Conclusion
Human, zoonotic and hybrid schistosomes continues to being incriminated in causing MGS significantly, hence posing a One Health challenge in management and control measures in resource poor settings. This calls for more tailored public health education campaigns in the endemic communities, awareness of MGS among primary healthcare workers and local animal health experts and collaborations among these stakeholders and National Schistosomiasis Control Programme in handling this burden and address it adequately.
Supporting information
Mainga et al. supplementary material
Acknowledgements
The study team acknowledge the generous support rendered by the Directors of Health and Social Services, District Medical Officers, District Environmental and Assistant Environmental Health Officers, District Laboratory Managers, Schistosomiasis Coordinators, Management and staff of Nsanje and Mangochi District Health Offices; the In-charges and Nurse-Midwives of Tengani and Mpondasi Health Centres; the Headteachers and teachers of Mthawira and Samama Primary Schools; and the study participants who took part in the HUGS Human longitudinal study, especially MGS sub-study. Much appreciation to Professor John Ellis at University of Sydney, Australia for testing STIs on the semen samples using their EasyScreen™ kit (SydPath, Sydney, Australia). Also grateful to the local community health workers: Abdul Salimu, Bossman Kutama, Christopher Thonje, Cynthia Issah, Grace Nyakamera, Harrison Makawa, Rester Fellow, Theresa Masauli, Witness Mapila, Angellina Mwenyewe, Flora Majawa, Caroline Mnthubula, Alice Kasonde, Doreen Chitsulo; and all traditional leaders and community members around Mthawira and Samama schools for their enthusiasm and support.
Supplementary material
The supplementary material for this article can be found at https://doi.org/10.1017/S0031182025100942.
Data availability statement
The datasets generated and analysed for this study has been included in this manuscript.
Author contributions
The authors contributed to this work as follows: SK, JM and JRS conceived and designed the study. SK, BM, FA, GD, DK1, AC, TN, DL, PC, DK2, GN, LK, EC, BN, GC, WK, HC, VK, AJ, SJ, JA, AOF, SR, AC, RC, LC, JC, PM, EJL, JM and JRS conducted data gathering. SK, BM, FA and LC performed statistical analyses. SK, BM, FA, GD, DK1, AC, TN, DL, PC, DK2, GN, LK, EC, BN, GC, WK, HC, VK, AJ, SJ, JA, AOF, SR, AC, RC, LC, JC, PM, EJL, JM and JRS wrote the article.
Financial support
This research received funding from National Institute for Health Research (NIHR) and Wellcome Trust through a Joint Investigator Award, grant number WT 220818/Z/20/Z.
Competing interests
The authors declare there are no conflicts of interest. The funders had no role in the design of the study, data gathering, statistical analyses and writing of the manuscript.
Ethical standards
The study was conducted in accordance with the Declaration of Helsinki and approved by the College of Medicine Research Ethics Committee (COMREC) of Kamuzu University of Health Sciences (KUHeS) in Malawi (approval number: P.08/21/3381) and LSTM Research Ethics Committee (LSTM REC) in the United Kingdom (approval number: 22-028). Informed consent to participate in the study was obtained from all of the participants.
References
- Buonfrate D, Ferrari TCA, Adegnika AA, Stothard JR and Gobbi FG (2025) Human schistosomiasis. The Lancet 405(10479), 658–670. [DOI] [PubMed] [Google Scholar]
- Bustinduy AL, Randriansolo B, Sturt AS, Kayuni SA, Leutscher PD, Webster BL, Van Lieshout L, Stothard JR, Feldmeier H and Gyapong M (2022) An update on female and male genital schistosomiasis and a call to integrate efforts to escalate diagnosis, treatment and awareness in endemic and non-endemic settings: The time is now. Advances in Parasitology 115, 1–44. [DOI] [PubMed] [Google Scholar]
- Cheesbrough M (2005) District Laboratory Practice in Tropical Countries, Part 2. Cambridge, UK: Cambridge University Press. [Google Scholar]
- Costain AH, MacDonald AS and Smits HH (2018) Schistosome egg migration: Mechanisms, pathogenesis and host immune responses. Frontiers in Immunology 9, 3042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cunningham L, Kayuni S, Juhász A, Makaula P, Lally D, Namacha G, Kapira D, Chammudzi P, Mainga B and Jones S (2024) A rapid DNA screening method using high-resolution melt analysis to detect putative Schistosoma haematobium and Schistosoma mattheei hybrids alongside other introgressing schistosomes. Frontiers in Tropical Diseases 5. doi: 10.3389/fitd.2024.1350680. [DOI] [Google Scholar]
- Juhász A, Makaula P, Cunningham LJ, Field L, Jones S, Archer J, Mainga B, Lally D, Namacha G and Kapira D (2024a) Revealing caprine schistosomiasis and its One Health importance in Malawi: A molecular epidemiological investigation augmented with a praziquantel treatment and GPS animal tracking pilot sub-study. One Health 19, 100918. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Juhász A, Makaula P, Cunningham LJ, Jones S, Archer J, Lally D, Namacha G, Kapira D, Chammudzi P, LaCourse EJ, Seto E, Kayuni SA, Musaya J and Stothard JR (2024b) Revealing bovine schistosomiasis in Malawi: Connecting human and hybrid schistosomes within cattle. One Health 100761. doi: 10.1016/j.onehlt.2024.100761. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kayuni S, Cunningham L, Mainga B, Kumwenda D, Jnr DL, Chammudzi P, Kapira D, Namacha G, Chisale A and Nchembe T (2024a) Detection of male genital schistosomiasis (MGS) associated with human, zoonotic and hybrid schistosomes in Southern Malawi. BMC Infectious Diseases 24(1), 839. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kayuni S, Lampiao F, Makaula P, Juziwelo L, Lacourse EJ, Reinhard-Rupp J, Leutscher PD and Stothard JR (2019a) A systematic review with epidemiological update of male genital schistosomiasis (MGS): A call for integrated case management across the health system in sub-Saharan Africa. Parasite Epidemiology and Control 4, e00077. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kayuni SA, Abdullahi A, Alharbi MH, Makaula P, Lampiao F, Juziwelo L, LaCourse EJ, Kumwenda JJ, Leutscher PDC and Geretti AM (2023b) Prospective pilot study on the relationship between seminal HIV-1 shedding and genital schistosomiasis in men receiving antiretroviral therapy along Lake Malawi. Scientific Reports 13(1), 14154. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kayuni SA, Alharbi MH, Makaula P, Lampiao F, Juziwelo L, LaCourse EJ and Stothard JR (2021) Male genital schistosomiasis along the shoreline of Lake Malawi: Baseline prevalence and associated knowledge, attitudes and practices among local fishermen in Mangochi District, Malawi. Frontiers in Public Health 9. doi: 10.3389/fpubh.2021.590695. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kayuni SA, Alharbi MH, Shaw A, Fawcett J, Makaula P, Lampiao F, Juziwelo L, LaCourse EJ, Verweij JJ and Stothard JR (2023a) Detection of male genital schistosomiasis (MGS) by real-time TaqMan® PCR analysis of semen from fishermen along the southern shoreline of Lake Malawi. Heliyon 9(7). doi: 10.1016/j.heliyon.2023.e17338. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kayuni SA, Musaya J and Stothard JR (2024b) Highlighting male genital schistosomiasis in Malawi. Trends in Parasitology 40(7), 546–548. doi: 10.1016/j.pt.2024.05.003. [DOI] [PubMed] [Google Scholar]
- Kayuni SA, Plam C, LaCourse EJ, Bartlett KE, Fawcett J, Shaw A, Makaula P, Lampiao F, Juziwelo L, de Dood CJ, Hoekstra PT, Verweij JJ, Leutscher PDC, van Dam GJ, van Lieshout L and Stothard JR (2019b) How can schistosome circulating antigen assays be best applied for diagnosing male genital schistosomiasis (MGS): An appraisal using exemplar MGS cases from a longitudinal cohort study among fishermen on the south shoreline of Lake Malawi. Parasitology 146(14), 1785–1795. doi: 10.1017/S0031182019000969. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Léger E, Borlase A, Fall CB, Diouf ND, Diop SD, Yasenev L, Catalano S, Thiam CT, Ndiaye A and Morrell A (2020) Prevalence and distribution of schistosomiasis in human, livestock, and snail populations in northern Senegal: a One Health epidemiological study of a multi-host system. The Lancet Planetary Health, 4(8), e330–e342. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Leutscher P, Ramarokoto C-E, Reimert C, Feldmeier H, Esterre P and Vennervald BJ (2000) Community-based study of genital schistosomiasis in men from Madagascar. The Lancet 355(9198), 117–118. [DOI] [PubMed] [Google Scholar]
- Madden F (1911) Two rare manifestations of Bilharziosis. The Lancet 178(4593), 754–755. [Google Scholar]
- Mawa PA, Kincaid-Smith J, Tukahebwa EM, Webster JP and Wilson S (2021) Schistosomiasis morbidity hotspots: Roles of the human host, the parasite and their interface in the development of severe morbidity. Frontiers in Immunology 12, 635869. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mbabazi PS, Andan O, Fitzgerald DW, Chitsulo L, Engels D and Downs JA (2011) Examining the relationship between urogenital schistosomiasis and HIV infection. PLoS Neglected Tropical Diseases 5(12), e1396. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ and Zhou XN (2018) Schistosomiasis. Nature Reviews Disease Primers 4(1), 13. doi: 10.1038/s41572-018-0013-8. [DOI] [PubMed] [Google Scholar]
- Midzi N, Mduluza T, Mudenge B, Foldager L and Leutscher PD (2017) Decrease in seminal HIV-1 RNA load after praziquantel treatment of urogenital schistosomiasis coinfection in HIV-positive men – an observational study. Open Forum Infectious Diseases 4(4), ofx199. doi: 10.1093/ofid/ofx199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rey O, Toulza E, Chaparro C, Allienne J-F, Kincaid-Smith J, Mathieu-Begné E, Allan F, Rollinson D, Webster BL and Boissier J (2021) Diverging patterns of introgression from Schistosoma bovis across S. haematobium African lineages. PLoS Pathogens 17(2), e1009313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rinaldi G, Young ND, Honeycutt JD, Brindley PJ, Gasser RB and Hsieh MH (2015) New research tools for urogenital schistosomiasis. The Journal of Infectious Diseases, 211(6), 861–869. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shukla JD, Kleppa E, Holmen S, Ndhlovu PD, Mtshali A, Sebitloane M, Vennervald BJ, Gundersen SG, Taylor M and Kjetland EF (2023) The association between Female genital schistosomiasis and other infections of the lower genital tract in adolescent girls and young women: A cross-sectional study in South Africa. Journal of Lower Genital Tract Disease 27(3), 291–296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stothard JR, Juhász A and Musaya J (2024) Schistosoma mattheei and zoonotic schistosomiasis. Trends in Parasitology 41(2), 87–90. doi: 10.1016/j.pt.2024.12.008. [DOI] [PubMed] [Google Scholar]
- Stothard JR, Kayuni SA, Al-Harbi MH, Musaya J and Webster BL (2020) Future schistosome hybridizations: Will all Schistosoma haematobium hybrids please stand-up! PLoS Neglected Tropical Diseases 14(7), e0008201. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Webster BL, Alharbi MH, Kayuni S, Makaula P, Halstead F, Christiansen R, Juziwelo L, Stanton MC, LaCourse EJ, Rollinson D, Kalua K and Stothard JR (2019) Schistosome Interactions within the Schistosoma haematobium group, Malawi. Emerging Infectious Diseases 25(6), 1245–1247. doi: 10.3201/eid2506.190020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- WHO (2005) Sexually Transmitted and Other Reproductive Tract Infections: a Guide to Essential Practice. Geneva, Switzerland: World Health Organization. [Google Scholar]
- WHO (2015) Female Genital Schistosomiasis: a Pocket Atlas for Clinical Health-care Professionals. Geneva, Switzerland: World Health Organization. [Google Scholar]
- WHO (2021) Guidelines for the Management of Symptomatic Sexually Transmitted Infections. 9789240024168. Geneva, Switzerland: World Health Organization. [PubMed] [Google Scholar]
- WHO (2022) WHO Guideline on Control and Elimination of Human Schistosomiasis. Geneva, Switzerland: World Health Organization. [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Mainga et al. supplementary material
Data Availability Statement
The datasets generated and analysed for this study has been included in this manuscript.